New hope for kids with rare blood disorder: drug cuts flares and steroid use
NCT ID NCT04965636
First seen Jan 04, 2026 · Last updated May 17, 2026 · Updated 23 times
Summary
This study tested a drug called mepolizumab in 16 children aged 6 to 17 with hypereosinophilic syndrome (HES), a rare condition where too many white blood cells cause damage. The goal was to see if the drug could reduce disease flares and the need for steroids. Over 52 weeks, most children had fewer flares and could lower their steroid doses, suggesting mepolizumab helps control the disease but does not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Buenos Aires, C1028AAP, Argentina
Conditions
Explore the condition pages connected to this study.